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Abstract
KRASmutations are the most frequent gain-of-function alterations in patients with lung adenocarcinoma (LADC) in theWestern
world. Although they have been identified decades ago, prior efforts to target KRAS signaling with single-agent therapeutic
approaches such as farnesyl transferase inhibitors, prenylation inhibition, impairment of KRAS downstream signaling, and
synthetic lethality screens have been unsuccessful. Moreover, the role of KRAS oncogene in LADC is still not fully understood,
and its prognostic and predictive impact with regards to the standard of care therapy remains controversial. Of note, KRAS-
related studies that included general non-small cell lung cancer (NSCLC) population instead of LADC patients should be very
carefully evaluated. Recently, however, comprehensive genomic profiling and wide-spectrum analysis of other co-occurring
genetic alterations have identified unique therapeutic vulnerabilities. Novel targeted agents such as the covalent KRAS G12C
inhibitors or the recently proposed combinatory approaches are some examples which may allow a tailored treatment for LADC
patients harboring KRASmutations. This review summarizes the current knowledge about the therapeutic approaches of KRAS-
mutated LADC and provides an update on the most recent advances in KRAS-targeted anti-cancer strategies, with a focus on
potential clinical implications.
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1 Introduction
Over the past 20 years, the formerly prevalent and widespread
pessimism regarding the therapeutic approaches and progno-
sis of advanced-stage non-small lung cancer (NSCLC) has
changed dramatically with the development of molecular pro-
filing, targeted therapeutic agents, immune checkpoint inhib-
itors, and precision medicine [1]. These efforts have offered
valuable insights into the mutational landscape of NSCLC,
including the Kirsten rat sarcoma viral oncogene homolog
(KRAS) mutation, which is the most common gain-of-
function alteration, accounting for approximately 30% of lung
adenocarcinomas (LADCs) in Western countries and about
10% of Asian LADCs [2, 3].
KRAS protein, encoded by the KRAS proto-oncogene, is a
small guanine triphosphatase (GTPase) that serves as a binary
switch in signal transduction for most receptor tyrosine ki-
nases including EGFR, MET, or ALK, and plays a key role
in regulating various cell functions [4, 5]. Oncogenic muta-
tions of the KRAS gene mostly occur in exon 2 at codon 12,
less frequently at codon 13 (3–5%) and rarely at exon 3 codon
61 (less than 1%) [5]. These alterations are missense muta-
tions that impair the ability of KRAS to hydrolyze GTP,
resulting in the constitutive activation of its effector pathways
and thus cancer development and progression [6]. Because of
its high frequency in LADC, several preclinical and clinical
investigations have been conducted, seeking effective thera-
peutic approaches targeting KRAS mutation. Still, to date, no
effective RAS inhibitors are currently used in routine clinical
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practice and the approaches for treating KRAS-mutant LADC
mirror those for treating NSCLC that lacks a known driver
mutation. In this review, we systematically analyze the clini-
cally relevant aspects of KRAS-mutant NSCLC, mainly fo-
cusing on the clinicopathological relevance, therapeutic impli-
cations, and new treatment opportunities.
2 Clinical relevance of KRAS mutations
in NSCLC
Molecular profiling of LADC patients shows that specific
demographic and clinicopathological characteristics are asso-
ciated with the presence of KRAS mutations. As national
surveys indicate, KRAS mutations mostly occur in
Caucasian or African-American patients and are far less fre-
quent in Asian patients [2, 3, 5]. Based on the findings of a
pooled analysis of resected NSCLC tumors, KRAS mutations
tend to be more common among women and patients of youn-
ger age, although only the latter remained significant at the
multivariate analysis (p = 0.044) [7, 8]. Notably, however, no
histology- or race-specific analyses were performed in the
above study with regards to the prevalence of KRAS muta-
tions. Interestingly, smoking also leaves a molecular finger-
print on KRAS, since transition mutations (G12D) are more
frequent in never smokers, whereas transversion mutations
(G12C and G12V) are more often found among former or
current smokers [9, 10]. In addition, smokers tend to have
genetically more complex KRAS-mutant tumors, with higher
mutational burden and higher frequency of major co-
occurring mutations in TP53 or STK11, than those who have
never smoked [10, 11]. The distribution of various KRAS
mutational subtypes among patients with different smoking
history is summarized in Fig. 1 [12].
Recently, attention has also been drawn to the special his-
tology and co-occurring mutations in KRAS-mutant lung can-
cer. Initial studies [13, 14] reported that although in a much
lower percentage, KRAS mutations might be present not only
in LADC but also in squamous cell lung cancer. However,
recent analysis using up-to-date differential diagnostic criteria
suggests that KRAS mutations do not occur in pure pulmo-
nary squamous cell lung carcinomas, and in case detected, it is
Fig. 1 KRAS mutational subtypes and smoking history in lung
adenocarcinoma (LADC) [12]. In current (a) and former (b) smokers,
KRAS G12C is the most common mutation, while KRAS G12D is the
most frequent mutation among never smokers (c). Overall (d), the most
frequently diagnosed KRAS mutational subtype in LADC patients is
KRAS G12C, followed by KRAS G12V, KRAS G12D, and KRAS
G12A
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confined to LADC components in squamous cancer [15]. The
other important issue is the clinical relevance of specific
KRAS mutations and the presence of these mutations in com-
bination with others. Variations in KRAS mutation subtypes
have been associated with distinct biological behaviors that
can lead to different clinical outcomes [16, 17]. For example,
tumors with KRASG12Cmutations exhibited higher ERK1/2
phosphorylation than those with KRAS G12D [3, 18]. In sup-
port of this, a recent study using KRAS mutation-driven
mouse models demonstrated higher efficacy of the MEK in-
hibitor selumetinib in KRAS G12C tumors compared with
KRAS G12D tumors [18]. Accordingly, distinct KRAS mu-
tations may lead to differential induction of signal transduc-
tion cascades and thus to specific drug sensitivity profiles
[19]. As for co-occurring mutations, double mutants (KRAS
and EGFR/ALK/BRAF) are rare in LADC, and KRAS muta-
tions are typically present as a single-driver mutation [20–22].
However, KRAS mutations co-occur commonly with muta-
tions in tumor suppressor genes including TP53, STK11 and
KEAP1/NFE2L2, and a growing body of evidence suggests
that these co-occurring mutations are associated with unique
tumor characteristics and biological behaviors [23]. Taken
together, the different amino acid substitutions in oncogenic
KRAS and the presence of coexisting mutations highlight the
need for genotype-specific analysis to identify clinically rele-
vant subgroups of patients that may ultimately influence treat-
ment decisions and prognosis [3].
3 The prognostic nature of KRAS mutations
in LADC
The prognostic power of KRAS mutation alone in the
general NSCLC population remains disputed. As in oth-
er malignancies, KRAS mutation was first reported to
be a negative prognostic factor in NSCLC in the 1980s
[24, 25]. However, although a considerable number of
publications verified this finding [26–30], these studies
were heterogeneous with regards to histology, tumor
stage, and methodology. Slebos [25], Ohtaki [28], and
Izar [29] investigated the prognosis in completely
resected LADCs, while later studies were performed in
stage IIIB–IV NSCLC patients [30–32]. The strongest
proof of KRAS being a negative prognostic factor in
NSCLC was reported by Mascaux et al. who conducted
a meta-analysis of 53 studies and found that KRAS
mutation correlated with a significantly worse prognosis
(hazard ratio [HR] 1.40; p = 0.01; HR 1.5 for LADCs;
p = 0.02) [33]. Contrary to this, in a study analyzing
998 LADCs, 318 of which harbored KRAS mutation,
the authors concluded that KRAS mutation was not an
individual prognostic factor [34]. One of the most com-
prehensive study, a meta-analysis of four individual
trials of adjuvant chemotherapy in 1500 NSCLC pa-
tients (among them 300 KRAS-mutant cases), also re-
ported that KRAS mutation had no prognostic value in
this setting [8]. However, a more recent study that in-
volved 1935 patients reported a clear advantage in over-
all survival (OS) for KRAS wild type patients, although
the presence of mutation did not impact progression-free
survival (PFS) [30]. Another recent pooled analysis of
studies assessing the role of KRAS mutation in circulat-
ing tumor DNA also indicated poorer PFS and OS in
KRAS-mutated genotypes [35].
The prevalence of KRASmutations varies among different
ethnic groups and ethnicity; therefore, it might also have an
impact on prognosis [5]. A meta-analysis of 41 trials and 6939
patients concluded that KRAS mutation was a negative prog-
nostic factor in NSCLC. Not surprisingly, these authors found
that KRASmutation only had a prognostic role in LADC (HR
was 1.39; 95% CI 1.24–1.55). The authors also looked at
ethnicity, comparing Asians and non-Asians, and found that
the HR for Asians was much larger than that for non-Asians,
implying that KRAS mutations have a worse prognosis in
Asian patients [36]. These results were also backed up by a
recent meta-analysis including over 9000 patients [37]. Of
note, patients with EGFR mutant LADC have a better prog-
nosis, and thus KRAS mutations’ prognostic power might be
influenced by the inclusion/exclusion and the proportion of
EGFR mutant cases in the study cohort.
Several studies suggest that due to the heterogeneity of
KRAS mutations, specific mutational subtypes might
have different effects on survival and treatment response.
For example, in a mutation subtype-specific analysis of
505 stage III–IV LADC patients treated with chemother-
apy, our group could not demonstrate prognostic or pre-
dictive potential of KRAS mutation. However, we found
that G12V mutant patients had higher response rates and
slightly longer PFS [31]. On the other hand, in two retro-
spective studies, the authors found a significantly shorter
OS in patients with KRAS G12C mutation [38].
Garassino et al. further highlighted the role of subtype-
specific KRAS mutation analysis when they conducted a
preclinical study assessing the in vitro chemosensitivity of
NSCLC cells. They found that G12V mutant tumor cells
were more sensitive to cisplatin and, furthermore, that
G12D mutation led to increased resistance to paclitaxel
and sensitivity to sorafenib, while G12C mutation was
associated with reduced response to cisplatin and in-
creased sensitivity to paclitaxel and pemetrexed [19].
Villaruz et al. found a slightly increased OS in patients
with G12C mutant tumors when compared with those
with tumors harboring other KRAS mutation subtypes
[34]. Table 1 summarizes a selection of the major studies
about the prognostic relevance of KRAS status in early-
and advanced-stage NSCLC.
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4 Predictive role of KRAS mutations
4.1 Predictive value of KRAS mutations for response
to chemotherapy
Despite the recent developments in NSCLC therapy, most pa-
tients with advanced-stage disease still receive platinum-based
chemotherapy. Most studies do not suggest KRAS mutation as
a predictive biomarker for response to chemotherapy. The pre-
dictive value of KRASmutation in NSCLCwas investigated in
themetastatic setting in patients receiving definitive chemother-
apy [39], in patients receiving adjuvant chemotherapy with ra-
diation after surgery [40], and also in the phase III TRIBUTE
trial where first-line carboplatin/paclitaxel plus erlotinib or pla-
cebo was compared in advanced-stage NSCLC [41]. In none of
the above settings did KRAS prove to be a predictive factor for
response rate, PFS, or OS.
More recently, results of the JBR10 trial, which studied the
effects of postoperative vinorelbine or cisplatin in patients with
resected stage IB or II NSCLC, were published. Remarkable
benefit from chemotherapy was only reported in KRAS wild
type patients; however, the difference did not prove to be statis-
tically significant (p = 0.29) [42]. Neoadjuvant and perioperative
chemotherapy sequences with carboplatin/paclitaxel or cisplatin/
gemcitabine were compared in the phase III IFCT-0002 trial.
KRAS-mutant tumors were shown to exhibit lower response to
cytotoxic chemotherapy in univariate analysis, although KRAS
mutation was not a significant predictor in multivariate analysis
[43]. A recent retrospective analysis of patients with advanced-
stage NSCLC also found that KRAS mutation is a predictor for
poor OS when treated with cytotoxic chemotherapy [44].
Furthermore, it was shown that the co-existence of TP53 muta-
tion predicts worse outcome [45]. Another aspect was shown in a
study conducted in an Asian cohort that analyzed outcomes in
patients receiving different chemotherapeutic regimens accord-
ing to the KRAS mutation status. Significantly poorer PFSs and
OSs were seen in patients with KRAS mutations when treated
with pemetrexed or gemcitabine but not in those receiving
taxanes [46]. Of note, a potential negative effect of KRAS codon
13 mutations was suggested by a clinical study [8] showing
significantly shorter PFS andOS in patients with suchmutations.
As previously mentioned, in a preclinical study by Garassino
et al., similar results were seen [19].
In summary, although KRAS mutations can be potentially
considered as predictive biomarkers for chemotherapy in
LADC, the exact type of mutation and the type of chemother-
apy should also be taken into consideration.
4.2 Predictive value of KRAS mutations for response
to targeted therapy
One of the major debates over the predictive role of KRAS-
mutant status of NSCLC patients takes place in the field of
EGFR-targeted therapies [5].Most published data, including a
meta-analysis of 22 studies, suggest that KRAS mutational
status is a significant negative predictor for EGFR tyrosine
kinase inhibitors (TKIs) [41, 47–49]. Accordingly, KRAS-
mutated patients treated with EGFR TKIs have a trend for
worse objective response rates (ORR), PFS, and OS compared
with patients without KRAS mutation [41, 48, 49]. However,
despite the convincing results, controversies still exist and not
all studies have reached the same conclusions [46, 50]. A
possible explanation for these discrepancies in the literature
might be that the response to EGFR TKI is greatly influenced
not only by the presence or absence of KRAS mutations but
also by the involved KRAS codons and the type of amino acid
substitutions [5, 51]. In support of this, a recent study showed
poorer treatment efficacy in the case of G12C and G12V
KRAS mutations but promising response rates in G12D and
G12S KRAS-mutant NSCLC patients treated with EGFR
TKIs [52]. All in all, patients with KRAS-mutant NSCLC
generally have a poor response to EGFR inhibitors; however,
due to the heterogeneity of various KRAS mutations, KRAS
mutational analysis cannot be recommended as a tool to select
NSCLC patients for EGFR TKI therapy.
4.3 Predictive value of KRAS mutations for response
to anti-vascular therapy
Although the RAS pathway has been shown to affect VEGF
expression, very few studies investigated the influence of
KRAS mutation on the efficacy of anti-angiogenic therapy
[53]. Only two groups reported that G12V, G12A [54], and
G12D [55] KRAS mutations are associated with poor out-
come in patients with colorectal cancer (CRC) receiving
bevacizumab. As for NSCLC, a phase II trial evaluated the
addition of neoadjuvant bevacizumab to chemotherapy and
found that no patients with KRAS mutation (0 out of 10)
demonstrated pathological response to neoadjuvant
bevacizumab and chemotherapy, while 35% of KRAS wild
type patients had significant response [56]. Furthermore, in a
recent single-center retrospective study from our group,
KRAS mutation, and especially G12D mutation, was shown
to be a predictor of significantly worse PFS and OS in
advanced-stage NSCLC patients treated with bevacizumab
plus platinum-based chemotherapy [57]. Table 2 summarizes
the available data on the predictive value of KRAS mutations
for therapeutic response in NSCLC.
4.4 Predictive value of KRAS mutations for response
to immune checkpoint inhibition therapy
Programmed cell death protein 1 (PD-1) expression has been
shown to be in close connection with KRAS status, and
KRAS mutations were described as possible biomarkers for
immune checkpoint inhibitors [58]. Also, a clinical benefit
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was reported to PD-1 inhibitors in KRAS-mutant patients
[59]. The elevated expression of programmed cell death li-
gand 1 (PD-L1) has been demonstrated in KRAS-mutant
cells, and it was also shown that ERK activation mediates
the upregulation of PD-L1 by KRAS mutations [60]. On the
contrary, Reiniger et al. did not find significant relations be-
tween PD-L1 expression and KRAS status in LADC [61]. It
was also reported that pembrolizumab (a PD-1 inhibitor) or an
ERK inhibitor might prevent CD3+ T cells becoming apopto-
tic by recovering tumor immunity thus preventing immune
escape [62]. In another study, however, Gettinger et al. found
increased response and survival with nivolumab monotherapy
and driver mutations of EGFR or KRAS did not show signif-
icant effect on survival or treatment response [63]. Altogether,
further clinical experience is needed to determine whether
KRAS mutation is a useful predictive factor for immunother-
apy in NSCLC. Table 2 includes three trials where the predic-
tive role of the KRAS mutational status for immune check-
point inhibition therapy was studied.
5 KRAS as a therapeutic target in NSCLC
5.1 Pitfalls of KRAS mutation targeting in NSCLC
Because of its high mutation frequency in NSCLC, KRAS is
an appealing target. However, the development of targeted
therapies for KRAS-mutant lung cancers has long been
marked by frustration [64–66]. For decades, KRAS was con-
sidered undruggable due to its exceptionally high affinity to
GTP/GDP, to the absence of known allosteric binding sites,
and to the presence of extensive post-transcriptional modifi-
cations [3, 7, 67]. KRAS protein shows high resistance against
small-molecule modulation, since it is a small protein with a
relatively smooth surface without clear binding pockets (be-
sides its GTP/GDP binding pocket) [68]. Under physiological
conditions in vivo, GTP almost exclusively occupies all po-
tential binding sites with extremely high affinity. The devel-
opment of KRAS inhibitors that achieve adequate blood con-
centration enough to displace GTP is, therefore, an almost
improbable task [68, 69]. In addition, the binding of small-
molecule inhibitors is also influenced by the interactions of
KRAS with other proteins that make the surface of the KRAS
protein shallow [68]. Importantly, indirect targeting of the
molecules within the KRAS signaling pathway also proved
to be almost ineffective due to the complexity and biological
heterogeneity of KRAS mutations in NSCLC [68, 70]. All in
all, despite enormous efforts, to date, almost all identified
compounds that could effectively and directly target mutant
KRAS have failed. However, with new technologies in drug
development and novel mechanistic insights into RAS biolo-
gy, new targeted therapeutic agents are under development
with promising preclinical activity (Fig. 2).
5.2 Targeting KRAS membrane anchorage
RAS proteins require membrane associations to become bio-
logically active [11, 68, 71]. The membrane anchorage of
KRAS is dependent on posttranslational modification of the
CAAXmotif by farnesyltransferases. Initial preclinical studies
with farnesyltransferase inhibitors (FTIs) demonstrated mod-
erate success in blocking tumor cells both in vitro and in vivo.
However, in the presence of FTIs, KRAS can be alternatively
prenylated by geranylgeranyl-transferase-I, thus overcoming
the effect of farnesyltransferase inhibition [6, 11, 72]. As ex-
pected, these results foreshadowed the disappointing clinical
trials with FTIs that failed to improve outcomes in KRAS-
mutant LADC patients [11, 73]. Still, some novel FTIs, when
combined with other inhibitors such as geranylgeranyl-
transferase inhibitors, showed potent anti-cancer activities in
KRAS-driven pancreatic tumors. Nevertheless, the efficacy of
these dual-functional therapeutic agents has not yet been in-
vestigated in LADC [74, 75]. Preclinical studies indicated that
lung cancer cells might be sensitive to prenylation inhibition
by bisphosphonates [76, 77]. Additionally, oral bisphospho-
nate use was associated with lower lung cancer risk among
never smoker postmenopausal women in a large prospective
study [78]. In isolated clinical cases, bisphosphonate therapy
caused the regression of the primary lesion and its hepatic
metastases in LADC [79]. Notably, however, a recent preclin-
ical study demonstrated that the aminobisphosphonate com-
pound zoledronic acid was ineffective in NSCLC cells harbor-
ing exon 2 codon 12 KRAS mutation, since this mutational
subtype leads to prenylation-independent activation of KRAS.
[80]. Nevertheless, the impact of the bisphosphonate treat-
ment in KRAS-mutant LADC patients remains to be fully
explored. Similarly, targeting other enzymes involved in the
post-prenylation processing of RAS (e.g., the RAS converting
CAAX endopeptidase 1 [Rce1] and isoprenylcysteine carbox-
yl methyltransferase [ICMT]) could as well inhibit the RAS-
driven tumorigenesis [81]. In the past years, numerous Rce1
and ICMT inhibitors have been designed and investigated in
several RAS-driven tumor entities. However, despite the en-
couraging results in vitro, the use of Rce1 and ICMT inhibi-
tors could impact the normal function of other proteins as well
in vivo, raising the questions about normal tissue toxicity and
possible side effects of these inhibitors [82].
5.3 Targeting KRAS downstream signaling pathways
Another feasible approach to treat KRAS-mutated NSCLC
might be to target the main signaling pathways controlled by
the constitutively active mutant KRAS (i.e., the RAF-MEK-
ERK or the PI3K/AKT/mTOR pathways). The inhibitors of
these signaling pathways have been tested in different RAS-
driven tumor types, and some of them showed promising ac-
tivity in preclinical models [11]. The results of conducted
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trials in KRAS-mutant NSCLC in regards to downstream sig-
naling pathway inhibition are summarized in Table 3.
Notably, one of the most promising therapeutic agent was
sorafenib, a multikinase inhibitor that showed promising re-
sults in preclinical settings and phase II clinical trials but only
modest clinical activity in phase III trials with ORRs generally
less than 10% and median PFS of approximately 3 months
[11, 83–85]. Clinical outcomes for single-agent allosteric
MEK inhibitors were also discouraging, since no clinical ac-
tivity of selumetinib or trametinib was observed [86, 87]. As
for other downstream inhibitors, the mTOR inhibitor
ridaforolimus showed a moderate increase in PFS, but its clin-
ical benefit was questionable with several side effects [88]. All
in all, clinical trials investigating the efficacy of KRAS down-
stream inhibitors in monotherapy provided limited clinical
benefit and substantial toxicity in most studies [11, 65] Yet,
recent preclinical studies with patient-derived xenograft
tumors highlighted the need for combination therapy in order
to fully block KRAS signaling in lung cancer [89]. These
results provide a strong therapeutic rationale to treat epithelial
KRAS-mutant lung cancer with ERBB and MEK inhibitors,
and mesenchymal-like KRAS-mutant lung cancer by com-
bined therapy with FGFR and MEK inhibitors [3, 89]. To
date, however, none of these findings have been translated
into the clinics.
5.4 Synthetic lethal vulnerabilities in KRAS-mutant
NSCLC
An alternative approach to direct targeting of KRAS-mutant
cancer genes involves targeting co-dependent vulnerabilities
or synthetic lethal partners that are preferentially essential for
KRAS oncogenesis [90]. The therapeutic ablation of these
secondary targets would hypothetically result in the selective
Fig. 2 A chronicle of KRAS mutation in lung cancer. Major biological
discoveries and key clinical trials. During its more than 30-year history,
our knowledge of KRAS mutation in lung cancer has progressed through
a series of phases. Although the relationship between RAS genes and
lung cancer was described in 1984, the first clinical trials investigating
the efficacy of indirect KRAS inhibitors were carried out only in the early
2000s. Since then, large numbers of both direct and indirect KRAS in-
hibitors have been developed and tested. However, until recently, efforts
to target the RAS family proteins were mostly ineffective in the clinics. At
the same time, in the past years, a worldwide awakening of interest led to
rapid translational progress and to the discovery of novel direct covalent
KRASG12C-inhibitors, some of which have been tested in clinical trials.
The renewed enthusiasm and biological and clinical progress have
changed the landscape of KRAS-mutated lung cancer and have led to
the first serious discussions of whether RAS is indeed a druggable target.
KRAS, Kirsten rat sarcoma viral oncogene homolog;MEK,MAPK/ERK
kinase; mTOR, mammalian target of rapamycin; MET, MET proto-
oncogene; Hsp90, heat shock protein 90; CDK4/6, cyclin-dependent ki-
nases 4/6; FAK, focal adhesion kinase; OS, overall survival
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death of KRAS-mutant but not KRAS wild type tumor cells
[11, 91]. One of the therapeutic approaches inducing synthetic
lethality included the proteasome inhibitor bortezomib [7].
However, in a small phase II clinical trial of 16 NSCLC pa-
tients with KRAS G12D mutation, bortezomib showed only a
modest disease control rate of 40%, only 1 objective response
(ORR 6%), and a PFS of 1 month [92]. The pharmacological
inhibition of cyclin-dependent kinase (CDK) was as well of
great clinical interest in the past years, and the selective
CDK4/6 inhibitor abemaciclib showed indeed promising re-
sults both in phases I and III clinical trials. Accordingly,
abemaciclib demonstrated significantly higher ORRs and
PFS than erlotinib in pretreated patients with advanced-stage
KRAS-mutant lung cancer patients, but no significant differ-
ence was observed in OS [93, 94]. The efficacy of other
CDK4/6 inhibitors (including palbociclib in combination ther-
apy with MEK inhibitors) is currently under investigation
(NCT02022982 and NCT03170206). Finally, preclinical
studies suggest that dual inhibition of discoidin domain recep-
tor 1 (DDR1) and Notch pathways also hampers the growth of
murine and human KRAS-mutant LADC; however, these re-
sults have not been yet validated in clinical trials [95].
5.5 Targeting direct regulators of KRAS activity
RAS protein is transformed into its active, GTP-bound state
by interaction with guanine nucleotide exchange factors
(GEFs) [96, 97]. The most-studied GEF for RAS is the protein
Son of Sevenless (SOS) (for which two isoforms, SOS1 and
SOS2, are known), which catalyzes the release of GDP and
allows the binding of the more abundant GTP [96, 97].
Accordingly, the selective inhibition of SOS1 with small-
molecule inhibitors such as the experimental BI 1701963
might allow KRAS blockade irrespective of KRAS mutation
type [96, 98–100]. This highly specific SOS1 inhibitor re-
duces both KRAS-GTP levels and MAPK signaling in cellu-
lar and animal models [100, 101]. Furthermore, preclinical
studies also suggest that BI 1701963 indeed blocks tumor
growth both in G12 and G13 KRAS-mutant tumors, and the
compound is selective for KRAS-mutant cell lines [100, 101].
The efficacy of the SOS1-binding pan-KRAS inhibitor BI
1701963 alone or in combination with the MEK inhibitor
trametinib in patients with KRAS-mutated solid tumors is
currently under investigation (NCT04111458).
5.6 Direct targeting of mutant KRAS
KRAS has been historically acknowledged a non-druggable
target. However, according to the results of the latest preclin-
ical findings, the landscape of G12C KRAS-mutated lung
cancer might change. After the discovery of new allosteric
regulatory pockets in GDP-RAS adjacent to the cysteine res-
idue of KRAS G12C, compounds that target the guanine
nucleotide-binding pocket (SML-8-73-1) or allele-specific in-
hibitors (ARS-853) have been reported [102–104]. Of note,
the effects of both SML-8-73-1 and ARS-853 on mutant
KRAS G12C are irreversible. SML-8-73-1 can covalently re-
act with KRASG12C, thus competing with GTP and GDP for
active site binding in a cellular context even in the presence of
a very high concentration of GTP [105]. Accordingly, by
locking the KRAS-GDP state, these GDP-derived inhibitors
can block the proliferative activity of the KRAS-mutant cells
[103, 104]. Despite their preclinical inhibitory effects on
KRAS G12C, follow-up studies also showed that the speci-
ficity of these inhibitors is somewhat low and may have off-
target effects when used in the clinics [103–105]. ARS-853,
on the other hand, does not compete with GTP for binding to
KRAS, since it binds to a pocket nearby the nucleotide-
binding pocket [106]. Hence, by making KRAS more prefer-
ential to accept GDP binding rather than GTP, it reduces the
KRAS-GTP levels bymore than 90% and increases the in vitro
hydrolytic reaction and thus locking the KRAS in the GDP-
bound state [103, 104, 106]. Accordingly, ARS-853 inacti-
vates the RAS signaling by a trapping mechanism, by which
KRAS G12C is trapped in the KRAS-GDP state [103, 104].
Importantly, similarly to SML-8-73-1 and SML-10-70-1,
ARS-853 only binds to KRAS G12C and has no inhibitory
effects on wild type KRAS and other types of mutant KRAS
[68]. These findings were recently translated into mouse mod-
el studies where ARS-1620, a similar covalent compound
with high potency and selectivity for KRAS G12C, induced
durable tumor regression in different patient-derived tumor
models [107]. Furthermore, recent studies also suggest a po-
tential synergistic activity when ARS-853 is combined with
receptor TKIs such as EGFR TKIs, indicating that covalent
G12C-specific inhibitors might indeed be promising therapeu-
tic agents used for the treatment of KRAS G12C-mutant
NSCLC patients [103, 104, 108, 109]. To date, however, no
clinical trials have been communicated with ARS-853 or
ARS-1620 in KRAS-mutant NSCLC.
5.7 Novel direct covalent KRAS-G12C inhibitors:
promising preclinical and clinical results
Recent discoveries of the aforementioned covalent KRAS
G12C-specific inhibitors have led to the first serious discus-
sions of whether RAS is indeed a druggable target. AMG 510
is a novel small molecule that covalently binds to the cysteine
amino acid of KRAS G12C-mutant proteins, and thus, it locks
KRAS in its inactive GDP-bound state irreversibly [110, 111].
In preclinical studies, treatment with AMG 510 induced the
regression of KRAS G12C tumors and improved the efficacy
of both chemotherapy and targeted agents [112]. Furthermore,
AMG 510 therapy also resulted in a pro-inflammatory tumor
microenvironment in immune-competent mice and produced
durable responses alone and in combination with immune
Cancer Metastasis Rev
checkpoint inhibitors as well [112, 113]. As for its clinical
benefit, in a recent phase I clinical trial in a small number of
pretreated NSCLC patients (NCT03600883), a partial re-
sponse was achieved in 54% and stable disease in 46% of
the patients with a disease control rate of 100% [66, 111].
Importantly, the treatment was well-tolerated with the absence
of dose-limiting toxicity and the occurrence of only a few
drug-related side effects [66, 111]. A multicenter phase II
clinical trial is currently ongoing [66]. MRTX 849 is another
potent, mutation-selective, and orally available irreversible
small-molecule inhibitor of KRAS G12C [114]. MRTX 894
also locks KRAS in an inactive GDP-bound state and blocks
the KRAS-dependent signal transduction and cancer cell via-
bility [3, 68]. In preclinical in vivo models, MRTX 894 treat-
ment was associated with potent antitumor activity in different
KRAS G12C-positive patient- and cell-derived tumors, with
an overall response rate of 65% [114–116]. Meanwhile, with
regards to its clinical efficacy, the first results of an ongoing
phase I/II clinical trial (NCT 03785249) suggest promising
clinical outcomes (especially in NSCLC patients) and favor-
able safety profile [68, 116]. Another potential direct KRAS
G12C inhibitor might be the investigational, orally available
JNJ-74699157 (ARS-3248), which is a new generation of the
KRAS G12C inhibitor ARS-1620. A multicenter phase I clin-
ical trial (NCT04006301) evaluating JNJ-74699157 started
the enrollment in July 2019 and is currently ongoing [66,
68]. Further potential KRAS G12C inhibitors under develop-
ment include the Eli Lilly drug LY3499446 (NCT04165031),
the Pfizer drug tetrahydroquinazoline derivatives (US
2019/0248767A1), and the AstraZeneca drug tetracyclic com-
pounds (WO 2019/110751 A1) [68].
5.8 Other therapeutic approaches to treat KRAS-
mutant NSCLC
Besides the need to develop new, single-agent therapeutic
compounds, the complexity of the RAS signaling pathway
underscores the necessity for a variety of combination therapy
as well. Consequently, combination screenings have been
conducted using ARS-1620, AMG 510, and MRTX 849 to
identify combinations that may enhance the therapeutic re-
sponse [68, 109]. Accordingly, adding mTOR and IGF1R
inhibitors to ARS-1620 greatly improves its effectiveness on
KRAS G12C-mutant lung cancer cells in vitro and in mouse
models [109]. Meanwhile, the combination of AMG 510 with
multiple agents including different MEK inhibitors or the
standard of care chemotherapeutic agent carboplatin resulted
in the synergistic killing of tumor cells in vitro, thus providing
rationale for this approach in the clinic [112]. As for the later-
mentioned direct KRAS G12C inhibitor, combinations of
MRTX 849 with agents including the HER family inhibitor
afatinib, the CDK4/6 inhibitor palbociclib, the SHP2 inhibitor
RMC-4550, and different mTOR pathway inhibitors
demonstrated enhanced response and marked tumor regres-
sion in several cell-line panels and tumor models, including
MRTX 849-refractory models as well [115]. Finally, since
preclinical works support the hypothesis that KRAS muta-
tions may be vulnerable to immune checkpoint inhibition,
the evaluation of clinical response to combination therapy of
direct and indirect KRAS inhibitors and immune checkpoint
inhibitors is also justified [117].
As for other therapeutic agents, AZD4785 is a KRAS an-
tisense oligonucleotide that targets the KRAS gene irrespec-
tive of its mutational status, thereby inhibiting the downstream
effector pathways [118]. Despite the encouraging preclinical
results showing significant antitumor activity and favorable
safety profile in mice and monkeys bearing KRAS-mutant
lung cancer, the first phase I clinical trial (NCT03101839)
failed, possibly because AZD4785 targets both mutant and
wild type KRAS protein [3, 118]. Accordingly, the develop-
ment of AZD4785 was later discontinued. As RAS proteins
are highly immunogenic, another potential therapeutic ap-
proach might be the adoptive transfer of genetically
engineered tumor antigen-specific T cells into patients with
KRAS-mutant tumors [119]. Pharmacological studies are still
in a very early stage; however, the first results indeed show an
in vitro efficacy of G12V-reactive CD4+ T cells against
KRAS G12V-mutant NSCLC cells [66, 120].
6 Open questions and future challenges
While direct KRAS G12C inhibitors have shown promising
results in some solid tumors including LADC, the develop-
ment of new potential therapeutic strategies for the treatment
of KRAS-mutated lung cancer is a work in progress, and
many questions remain.
1. Despite the promising results achieved with direct
KRAS G12C inhibitors, approximately half of the G12C-
mutant lung cancer patients show only a partial response to
these therapeutic agents [121]. The mechanism of how cancer
cells bypass inhibition to prevent maximal response to therapy
is not yet fully understood. A possible explanation might be
that some quiescent cells produce new KRAS G12C in re-
sponse to suppressed mitogen-activated protein kinase output,
which is maintained in its active, drug-insensitive state by the
epidermal growth factor receptor and aurora kinase signaling
[121]. Since the inhibitors bind only to the inactive conforma-
tion of KRAS, the cells with these adaptive changes bypass
the effects of KRASG12C inhibitors and resume to proliferate
[121]. This adaptive process must be overcome if we are to
achieve complete and durable responses in the clinic [121].
2. Distant organ metastases with unique microenvironmental
features occur frequently in lung cancer. Some of these special
microenvironments, including the blood-brain barrier in case of
brain metastases, represent a potential challenge for targeted
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therapeutic agents to reach the tumor cells in appropriate concen-
trations. Thereby, it is still an open question which of the direct
covalent KRAS inhibitors will be able to penetrate the blood-
brain barrier or other metastatic site-specific barriers.
3. Whether direct inhibition of KRAS with these new com-
pounds in monotherapy is sufficient also remains an open
question. Accordingly, future studies evaluating the clinical
efficacy and tolerability of direct covalent KRAS inhibitors
in combination therapy with anti-EGFR therapies, immune
checkpoint inhibitors, or upstream and downstream RAS sig-
naling inhibitors are needed.
4. AlthoughKRASG12C inhibitors are puttingKRAS’s non-
druggability reputation to the test, only 35 to 45% of all KRAS-
mutant LADC patients harbor this variant [12]. Therefore, selec-
tive inhibitors or broader-acting pan-KRAS agents are needed for
patients with non-G12C KRAS mutations. In non-clinical stud-
ies, the novel SOS1 inhibitors demonstrated increased antitumor
activity irrespective of KRAS mutation type, yet these findings
were not yet translated into the clinics.
7 Conclusions
To summarize, although KRAS mutations represent one
of the most common oncogenic driver mutations in lung
cancer, KRAS has been historically acknowledged a
non-druggable target. Indeed, to date, no effective
RAS inhibitors are used in routine clinical practice.
Furthermore, the predictive role of KRAS mutation in
patients receiving chemo-, targeted, anti-vascular, or im-
munotherapy needs to be clarified. Nevertheless, recent
data on the novel direct covalent KRAS G12C inhibi-
tors AMG 510 and MRTX 849 appear to be promising
both in preclinical and clinical settings. Other therapeu-
tic approaches such as combinatory therapy with
targeted agents, immune checkpoint inhibitors, KRAS
downstream inhibitors, or the newly developed direct
covalent inhibitors are also encouraging but require fur-
ther clinical testing. At the same time, mechanisms of
adaptive resistance that limits the therapeutic potential
of conformation-specific KRAS G12C inhibition might
represent a possible future challenge that must be over-
come for durable responses. All in all, despite the his-
torical lack of progress, the emergence of new promis-
ing agents might change the therapeutic landscape of
KRAS-mutant LADC. Yet, many questions remain and
the clinical relevance of KRAS gene mutations warrants
further investigations.
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